Regeneron Pharmaceuticals, Inc.
Close on Nov 19, 2026Market cap $95.52BP/E 20.4Yield –
Total Consolidated Revenues Recorded by Regeneron của Regeneron Pharmaceuticals
Total Consolidated Revenues Recorded by Regeneron ($M) ($M)
Total Consolidated Revenues Recorded by Regeneron của Regeneron Pharmaceuticals: $5,116M trong Q3 2026, tăng 36.3% so với cùng kỳ năm trước.
Số của Q3 2026 lấy từ đâu
Nguồn: Form 10-Q (filed 2026-10-30) ↗
Được báo cáo trong Form 10-Q / 10-K Consolidated Statements of Operations.
Lịch sử theo quý
Rê chuột vào một số để xem câu chữ đã đọc ra số đó; số tự tính sẽ hiện công thức
| Kỳ | Kết thúc | Total Consolidated Revenues Recorded by Regeneron ($M) ($M) | So với cùng kỳ | Nguồn |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 5,116 | +36.3% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 4,291 | +16.7% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,605 | +19.0% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,884 | +2.5% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,754 | +0.9% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,676 | +3.6% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,029 | -3.7% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,789 | +10.3% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 3,721 | +10.6% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,547 | +12.3% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,145 | -0.5% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,434 | +0.6% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,363 | +14.5% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,158 | +10.5% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,162 | +6.6% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,414 | -31.0% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,936 | -15.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,857 | -44.4% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 2,965 | +17.3% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,952 | +104.4% | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,453 | +50.5% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 5,139 | +163.2% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 2,529 | +38.3% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,423 | +30.0% | Form 10-K (filed 2021-02-08) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,294 | +31.6% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,952 | +23.7% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,828 | +33.2% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,864 | -3.3% | Form 10-K (filed 2021-02-08) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,744 | +4.8% | Form 10-K (filed 2021-02-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,578 | -1.9% | Form 10-K (filed 2021-02-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,373 | -9.2% | Form 10-K (filed 2021-02-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,928 | +21.8% | Form 10-K (filed 2020-02-07) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,664 | +10.8% | Form 10-K (filed 2020-02-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,608 | +9.4% | Form 10-K (filed 2020-02-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,512 | +14.6% | Form 10-K (filed 2020-02-07) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,582 | +29.0% | Form 10-K (filed 2019-02-07) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,501 | +23.0% | Form 10-K (filed 2019-02-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,470 | +21.2% | Form 10-K (filed 2019-02-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,319 | +9.8% | Form 10-K (filed 2019-02-07) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,227 | +11.7% | Form 10-K (filed 2018-02-08) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,220 | +7.3% | Form 10-K (filed 2018-02-08) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,213 | +21.4% | Form 10-K (filed 2018-02-08) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,201 | +38.1% | Form 10-K (filed 2018-02-08) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,098 | +36.9% | Form 10-K (filed 2017-02-09) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,137 | +56.7% | Form 10-K (filed 2017-02-09) ↗ |
| Q2 2015 | Jun 30, 2015 | 999 | +50.0% | Form 10-K (filed 2017-02-09) ↗ |
| Q1 2015 | Mar 31, 2015 | 870 | +39.0% | Form 10-K (filed 2017-02-09) ↗ |
| Q4 2014 | Dec 31, 2014 | 802 | +31.4% | Form 10-K (filed 2015-02-12) ↗ |
| Q3 2014 | Sep 30, 2014 | 726 | +21.6% | Form 10-Q (filed 2014-11-04) ↗ |
| Q2 2014 | Jun 30, 2014 | 666 | +45.5% | Form 10-Q (filed 2014-08-05) ↗ |
| Q1 2014 | Mar 31, 2014 | 626 | +42.3% | Form 10-Q (filed 2014-05-08) ↗ |
| Q4 2013 | Dec 31, 2013 | 610 | +47.2% | Form 10-K (filed 2014-02-13) ↗ |
| Q3 2013 | Sep 30, 2013 | 597 | +39.6% | Form 10-Q (filed 2013-11-05) ↗ |
| Q2 2013 | Jun 30, 2013 | 458 | +50.3% | Form 10-Q (filed 2013-08-06) ↗ |
| Q1 2013 | Mar 31, 2013 | 440 | +89.7% | Form 10-Q (filed 2013-05-03) ↗ |
| Q4 2012 | Dec 31, 2012 | 415 | +237.1% | Form 10-K (filed 2013-02-15) ↗ |
| Q3 2012 | Sep 30, 2012 | 428 | +316.1% | Form 10-Q (filed 2012-10-24) ↗ |
| Q2 2012 | Jun 30, 2012 | 304 | +182.4% | Form 10-Q (filed 2012-07-25) ↗ |
| Q1 2012 | Mar 31, 2012 | 232 | +106.6% | Form 10-Q (filed 2012-04-26) ↗ |
| Q4 2011 | Dec 31, 2011 | 123 | -8.0% | Form 10-K (filed 2012-02-21) ↗ |
| Q3 2011 | Sep 30, 2011 | 103 | -3.0% | Form 10-Q (filed 2011-10-27) ↗ |
| Q2 2011 | Jun 30, 2011 | 108 | -7.0% | Form 10-Q (filed 2011-07-28) ↗ |
| Q1 2011 | Mar 31, 2011 | 112 | +8.4% | Form 10-Q (filed 2011-05-03) ↗ |
| Q4 2010 | Dec 31, 2010 | 134 | +38.1% | Form 10-K (filed 2012-02-21) ↗ |
| Q3 2010 | Sep 30, 2010 | 106 | -9.8% | Form 10-Q (filed 2010-10-28) ↗ |
| Q2 2010 | Jun 30, 2010 | 116 | +28.8% | Form 10-Q (filed 2010-07-28) ↗ |
| Q1 2010 | Mar 31, 2010 | 104 | – | Form 10-Q (filed 2011-05-03) ↗ |
| Q4 2009 | Dec 31, 2009 | 96.8 | – | Form 10-K (filed 2011-02-17) ↗ |
| Q3 2009 | Sep 30, 2009 | 118 | – | Form 10-Q (filed 2010-10-28) ↗ |
| Q2 2009 | Jun 30, 2009 | 90 | – | Form 10-Q (filed 2010-07-28) ↗ |
Phân tách
total Consolidated Revenues Recorded by Regeneron gồm những gì
- Total Consolidated Revenues YoY Growth (%)36.0% · Q3 2026
- Net Product Sales Recorded by Regeneron ($M)1,805 · Q3 2026
- Total Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M)3,001 · Q3 2026
- Other Revenue (Royalties, BARDA Funding & Contract Manufacturing) ($M)310 · Q3 2026
- Revenues by Customer Location — United States [legacy through FY22] ($M)1,699 · Q4 2022
Trích dẫn dữ liệu này
StockData. (2026). Total Consolidated Revenues Recorded by Regeneron ($M) của Regeneron Pharmaceuticals, theo quý Q2 2009–Q3 2026 [Bộ dữ liệu]. Tổng hợp từ Hồ sơ SEC và tài liệu dành cho nhà đầu tư của Regeneron Pharmaceuticals. https://stockdatahq.com/stocks/regn/kpis/rev-total
Xem mọi chỉ số ở bảng KPI của Regeneron Pharmaceuticals. Dữ liệu cập nhật Nov 4, 2026.
See a number that looks wrong?